NEW ORLEANS — Adding daratumumab to bortezomib, lenalidomide and dexamethasone led to improved health-related quality of life for transplant-eligible patients with newly diagnosed multiple myeloma, study results showed.
The findings, presented at ASH Annual Meeting and Exposition, also showed reduced pain symptoms with the addition of daratumumab (Darzalex, Janssen), an anti-CD38 monoclonal antibody, to the standard induction/consolidation regimen with autologous hematopoietic stem cell transplant (HSCT) and lenalidomide (Revlimid, Bristol Myers Squibb) maintenance.
“Overall, these
